Fore Capital’s Novo Nordisk NVO Stock Holding History

Fore Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,000	Closed	-$1.61M	–	64
2025 Q3	$1.61M	Buy	+29,000	New	+$1.7M	0.46%	27

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fore Capital's NVO Position: Q4 2025 in Review

Fore Capital sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 29,000 shares — an estimated $1.61M sold.

Fore Capital first reported a position in NVO in Q3 2025 and held it in 1 quarter. The position peaked at $1.61M in Q3 2025. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Fore Capital reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Fore Capital sold 29,000 Novo Nordisk shares in Q4 2025, an estimated $1.61M.
Fore Capital first reported a position in Novo Nordisk in Q3 2025 and held it in 1 quarter.
Fore Capital's Novo Nordisk position peaked at $1.61M in Q3 2025.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Fore Capital's 13F filing for Q4 2025, filed 11 Feb 2026.